Extended Data Fig. 7: PPP2R1A mutation leading to AKT activations.
From: PPP2R1A mutations portend improved survival after cancer immunotherapy
a. Validation of PPP2R1A mutation status in the parental and CRISPR-edited HEC50B cell lines by Sanger-sequencing. b. Expression of AKT and pAKT-T308 in the parental and CRISPR-edited HEC50B cells by immunoblot. c. Validation of PPP2R1A mutation status in the parental and CRISPR-edited OVCAR429 cell lines by Sanger-sequencing. d. Expression of AKT and pAKT-T308 in the parental and CRISPR-edited OVCAR429 cells by immunoblot. e. Different immune signatures in pretreatment samples with and without AKT alterations. For b and d, three independent experiments were performed, and representative results were shown. For gel source data, see Supplementary Fig. 1.
